James Roach

7 POSTS 0 COMMENTS
James Roach is an experienced NHS director having held roles in hospitals, clinical commissioning groups and in joint roles with social care. James runs Conclusio Limited, developing innovative solutions in health and care systems in UK and China.

Latest articles

COVID-19 one year on - key changes

COVID-19 and key changes one year on

One year on from the first confirmed case of COVID-19 in the UK, Oli Hudson, Content Director at Wilmington Healthcare, takes a look at...
FDA approval for Roche’s Actemra/RoActemra in lung disease

FDA approves Roche’s Actemra/RoActemra for interstitial lung disease

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in...
Pre-clinical work completed for novel COVID-19 immunotherapy

Pre-clinical work completed for novel COVID-19 immunotherapy

ISA Pharmaceuticals has announced that it has completed pre-clinical work for ISA106, a novel COVID-19 immunotherapy and is planning clinical trials. A phase 1...

Popular articles

Image of a person descending a ladder over coronavirus to show New Normal, New Thinking: Life Post COVID-19

New Normal, New Thinking: Life Post COVID-19

New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Image of a scientist at their lab to show Study shows existing anti-parasitic drug kills coronavirus within 48 hours

Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours

A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
Nasal spray to protect against COVID-19 is ready for use in humans

Nasal spray to protect against COVID-19 is ready for use in humans

A nasal spray to provide protection against the COVID-19 virus has been formulated by researchers at the University of Birmingham, UK, using compounds already...
FDA approval for Roche’s Actemra/RoActemra in lung disease

FDA approves Roche’s Actemra/RoActemra for interstitial lung disease

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in...
COVID-19 one year on - key changes

COVID-19 and key changes one year on

One year on from the first confirmed case of COVID-19 in the UK, Oli Hudson, Content Director at Wilmington Healthcare, takes a look at...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription